Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO Annual Meeting finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Bristol Myers Squibb Co. (BMY) announced Monday that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
The European Medicines Agency has recommended Fruzaqla, Truqap, and Eribulin Baxter for use in the treatment of specific colorectal and breast cancers.
Agenus Inc. (AGEN) stock is falling over 14 percent on Friday morning after the announcement of updated data from its phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic colorectal cancer, that is not microsatellite instability-high or MSS, or deficient mismatch repair or dMMR.